ECSP077235A - Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa - Google Patents

Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa

Info

Publication number
ECSP077235A
ECSP077235A EC2007007235A ECSP077235A ECSP077235A EC SP077235 A ECSP077235 A EC SP077235A EC 2007007235 A EC2007007235 A EC 2007007235A EC SP077235 A ECSP077235 A EC SP077235A EC SP077235 A ECSP077235 A EC SP077235A
Authority
EC
Ecuador
Prior art keywords
compounds
trifluoro
methyl
benzamids
replaced
Prior art date
Application number
EC2007007235A
Other languages
English (en)
Inventor
Pascal Furet
Patricia Imbach
Georg Martiny-Baron
Giorgio Caravatti
Lawrence Blas Perez
Tao Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP077235A publication Critical patent/ECSP077235A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La invención se refiere a compuestos de benzamida sustituida por trifluoro-metilo de la Fórmula (I), a productos farmacéuticos que comprenden estos compuestos, a su uso como o para la fabricación de productos farmacéuticos, en particular como inhibidores de las quinasas de proteína y/o el tratamiento de una condición, trastorno, o estado de enfermedad mediado por la actividad de una quinasa de proteína, y/o una enfermedad proliferativa, a métodos de tratamiento que comprenden administrar los compuestos, en especial de tratamiento terapéutico y profiláctico, a métodos para la fabricación de los compuestos, y a intermediarios novedosos y pasos parciales para su síntesis.
EC2007007235A 2004-08-11 2007-02-09 Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa ECSP077235A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0417905.7A GB0417905D0 (en) 2004-08-11 2004-08-11 Organic compounds

Publications (1)

Publication Number Publication Date
ECSP077235A true ECSP077235A (es) 2007-03-29

Family

ID=33017336

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2007007235A ECSP077235A (es) 2004-08-11 2007-02-09 Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa

Country Status (17)

Country Link
US (2) US20060035897A1 (es)
EP (1) EP1778640A1 (es)
JP (1) JP2008509187A (es)
KR (1) KR20070046851A (es)
CN (2) CN101696188A (es)
AU (1) AU2005270313A1 (es)
BR (1) BRPI0514288A (es)
CA (1) CA2575316A1 (es)
EC (1) ECSP077235A (es)
GB (1) GB0417905D0 (es)
IL (1) IL181169A0 (es)
MA (1) MA28822B1 (es)
MX (1) MX2007001642A (es)
NO (1) NO20071300L (es)
RU (1) RU2007108861A (es)
TN (1) TNSN07048A1 (es)
WO (1) WO2006015859A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054916A1 (en) † 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1878727A4 (en) * 2005-04-28 2013-11-13 Kyowa Hakko Kirin Co Ltd 2-AMINOQUINAZOLINE DERIVATIVES
CN102861338A (zh) * 2006-04-05 2013-01-09 诺瓦提斯公司 用于治疗癌症、包含bcr-abl/c-kit/pdgf-r tk抑制剂的组合
MX2009000374A (es) * 2006-07-13 2009-01-27 Novartis Ag Uso de benzamidas substituidas con trifluorometilo en el tratamiento de trastornos neurologicos.
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
ATE501124T1 (de) * 2006-09-05 2011-03-15 Amgen Inc Phthalazin-, aza- und diazaphthalazinverbindungen und anwendungsverfahren
US20100173426A1 (en) * 2006-12-19 2010-07-08 Johnson Faye M Biomaker identifying the reactivation of stat3 after src inhibition
EP2121692B1 (en) 2006-12-22 2013-04-10 Incyte Corporation Substituted heterocycles as janus kinase inhibitors
WO2008136948A1 (en) 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use
WO2008137176A1 (en) * 2007-05-07 2008-11-13 Amgen Inc. Pyrazolo-pyridinone compounds, process for their preparation, and their pharmaceutical use
US20100292292A1 (en) * 2007-09-13 2010-11-18 Link Medicine Corporation Treatment of Neurodegenerative Diseases Using Indatraline Analogs
WO2009117156A1 (en) * 2008-03-21 2009-09-24 Amgen Inc. Pyrazolo-pyrazinone compounds and methods of use thereof
JPWO2009131173A1 (ja) 2008-04-23 2011-08-18 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
EP2334674B1 (en) 2008-08-29 2012-06-06 Amgen, Inc Pyridazino- pyridinone compounds for the treatment of protein kinase mediated diseases.
WO2010025202A1 (en) 2008-08-29 2010-03-04 Amgen Inc. PYRIDO[3,2-d]PYRIDAZINE-2(1H)-ONE COMPOUNDS AS P38 MODULATORS AND METHODS OF USE THEREOF
US8497269B2 (en) 2008-10-10 2013-07-30 Amgen Inc. Phthalazine compounds as p38 map kinase modulators and methods of use thereof
WO2010042646A1 (en) 2008-10-10 2010-04-15 Amgen Inc. Aza- and diaza-phthalazine compounds as p38 map kinase modulators and methods of use thereof
CN102316738A (zh) * 2009-02-18 2012-01-11 盛泰萨路申有限公司 作为激酶抑制剂的酰胺类
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
KR101457027B1 (ko) 2009-06-09 2014-10-31 캘리포니아 캐피탈 에쿼티, 엘엘씨 트리아진 유도체와 이들의 치료적 용도
CN102573473B (zh) 2009-06-09 2015-05-27 加利福尼亚资本权益有限责任公司 用作hedgehog 信号转导抑制剂的异喹啉、喹啉和喹唑啉衍生物
EP2762142A1 (en) * 2009-10-30 2014-08-06 ARIAD Pharmaceuticals, Inc. Compositions for treating cancer
CN102675289B (zh) * 2011-03-18 2014-11-05 浙江大德药业集团有限公司 作为蛋白激酶抑制剂的n-苯基苯甲酰胺衍生物
US20140323519A1 (en) * 2011-04-26 2014-10-30 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
CN111904960A (zh) * 2020-05-19 2020-11-10 合肥合源药业有限公司 一种固体分散体及药用组合物
KR102463217B1 (ko) * 2020-07-13 2022-11-07 한국과학기술연구원 단백질 키나아제 저해 활성을 갖는 4-아미노퀴나졸린-2-카복스아미드 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
CN111925331A (zh) * 2020-07-14 2020-11-13 上海毕得医药科技有限公司 一种6-溴酞嗪的合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6587829B1 (en) * 1997-07-31 2003-07-01 Schering Corporation Method and apparatus for improving patient compliance with prescriptions
US6523009B1 (en) * 1999-11-06 2003-02-18 Bobbi L. Wilkins Individualized patient electronic medical records system
US20030236682A1 (en) * 1999-11-08 2003-12-25 Heyer Charlette L. Method and system for managing a healthcare network
US6684276B2 (en) * 2001-03-28 2004-01-27 Thomas M. Walker Patient encounter electronic medical record system, method, and computer product
GB0217757D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Novel compounds
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use

Also Published As

Publication number Publication date
MA28822B1 (fr) 2007-08-01
RU2007108861A (ru) 2008-09-20
MX2007001642A (es) 2007-04-10
CA2575316A1 (en) 2006-02-16
US20080096883A1 (en) 2008-04-24
NO20071300L (no) 2007-04-19
WO2006015859A1 (en) 2006-02-16
AU2005270313A1 (en) 2006-02-16
IL181169A0 (en) 2007-07-04
CN101039914A (zh) 2007-09-19
KR20070046851A (ko) 2007-05-03
GB0417905D0 (en) 2004-09-15
US20060035897A1 (en) 2006-02-16
JP2008509187A (ja) 2008-03-27
BRPI0514288A (pt) 2008-06-10
EP1778640A1 (en) 2007-05-02
CN101696188A (zh) 2010-04-21
TNSN07048A1 (en) 2008-06-02

Similar Documents

Publication Publication Date Title
ECSP077235A (es) Benzamidas sustituidas por trifluoro-metilo como inhibidores de quinasa
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CR8102A (es) Derivados de pirazolo- quinazolina, procedimiento para preparacion y su uso como inhibidores de quinasa
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
DOP2010000013A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
DOP2010000012A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o pi3k
DOP2010000242A (es) Pirrolo[2,3-d]piridinas y usos de las mismas como inhibidores de cinasa de tirosina
CR20110270A (es) Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades
ECSP088329A (es) Nuevos diazaespiroalcanos y su uso para el tratamiento de enfermedades mediadas por ccr8
ECSP088821A (es) Derivados de tioxantina y su uso como inhibidores de la mpo
CL2021000514A1 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CR8778A (es) Revestimientos de azucar y metodos para estos
UY32190A (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibdores de quinasas dependientes de ciclina (cdk), produccion y uso de los mismos como productos medicinales
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
UY29358A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
ATE496899T1 (de) Tetrahydro- und dihydrochinazolinone
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
UY28460A1 (es) Compuestos de aminotriazol útiles como inhibidores de quinasas de proteinas